Can TRIS (Trishydroxymethylaminomethane) be used as a pharmaceutical intermediate?

Pharmaceutical intermediates refer to chemical raw materials or chemical products used in the process of pharmaceutical synthesis. From the development history of China's pharmaceutical intermediates industry, after nearly 30 years of development, pharmaceutical intermediates have developed from a small branch of the chemical industry to a new industry with an output value of billions of yuan, and its market competition is becoming increasingly fierce. Now Desheng Xiaobian will introduce several common pharmaceutical intermediates for you.

Tris (trimethylol aminomethane)

Tris actually has another name, tromethamine, which is also related to its role in the field of medicine. In the field of medicine, Tris is also widely used in medicine. Tris is the intermediate of fosfomycin tromethamine. Fosfomycin tromethamine is a kind of broad-spectrum antibacterial drug which was launched in the late 1980s. Its bioavailability is 3 ~ 6 times of that of fosfomycin calcium, which is more suitable for the treatment of urinary tract infection and other diseases. Tris, as an organic amine, can form water-soluble double salt with insoluble substances with acidic groups. The most common eye drops containing Tris are ketorolac tromethamine eye drops.

Methyl 4,4 '- dimethoxyacetoacetate

Methyl 4,4 '- dimethoxyacetoacetate is an important intermediate of nifedipine for the treatment of cardiovascular and cerebrovascular diseases. It is the leading drug for the treatment of cardiovascular and cerebrovascular diseases in the international market, but it has not been produced in China. Methyl 4,4 '- dimethoxyacetoacetate was synthesized from glyoxylic acid and trimethyl orthoformate in the presence of concentrated sulfuric acid. The latter reacted with methyl acetate and sodium methoxide to obtain methyl 4,4' - dimethoxyacetoacetate.

Pazopanib

Pazopanib is a new oral angiogenesis inhibitor developed by GlaxoSmithKline company, which can interfere with the angiogenesis required for the survival and growth of refractory tumors. It targets vascular endothelial growth factor receptor (VEGFR) and works by inhibiting the angiogenesis of tumor blood supply. It is suitable for the treatment of advanced renal cell carcinoma (a type of renal carcinoma with cancer cells found in renal tubules), soft tissue sarcoma (STS), epithelial ovarian cancer and non-small cell lung cancer (NSCLC).

To sum up, Tris can be used as pharmaceutical intermediates. In addition to pharmaceutical applications, it can also be widely used in in vitro diagnosis, biopharmaceutical, cosmetics, paint and other industries. Desheng is a professional Tris reagent manufacturer, and its customers are the most in the application of buffers. Due to its high buffering efficiency and guaranteed quality, there are more than 50 stable cooperation customers at home and abroad .